Literature DB >> 21618891

Histamine in neurotransmission and brain diseases.

Saara Nuutinen1, Pertti Panula.   

Abstract

Apart from its central role in the mediation of allergic reactions, gastric acid secretion and inflammation in the periphery, histamine serves an important function as a neurotransitter in the central nervous system. The histaminergic neurons originate from the tuberomamillary nucleus of the posterior hypothalamus and send projections to most parts of the brain. The central histamine system is involved in many brain functions such as arousal, control of pituitary hormone secretion, suppression ofeating and cognitive functions. The effects of neuronal histamine are mediated via G-protein-coupled H1-H4 receptors. The prominent role of histamine as a wake-promoting substance has drawn interest to treat sleep-wake disorders, especially narcolepsy, via modulation of H3 receptor function. Post mortem studies have revealed alterations in histaminergic system in neurological and psychiatric diseases. Brain histamine levels are decreased in Alzheimer's disease patients whereas abnormally high histamine concentrations are found in the brains of Parkinson's disease and schizophrenic patients. Low histamine levels are associated with convulsions and seizures. The release of histamine is altered in response to different types of brain injury: e.g. increased release of histamine in an ischemic brain trauma might have a role in the recovery from neuronal damage. Neuronal histamine is also involved in the pain perception. Drugs that increase brain and spinal histamine concentrations have antinociceptive properties. Histaminergic drugs, most importantly histamine H3 receptors ligands, have shown efficacy in many animal models of the above-mentioned disorders. Ongoing clinical trials will reveal the efficacy and safety of these drugs in the treatment of human patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21618891     DOI: 10.1007/978-1-4419-8056-4_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  31 in total

1.  Purification, crystallization and preliminary X-ray analysis of human histidine decarboxylase.

Authors:  Hirofumi Komori; Yoko Nitta; Hiroshi Ueno; Yoshiki Higuchi
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-05-23

2.  Neurometabolic roles of ApoE and Ldl-R in mouse brain.

Authors:  Jieun Lee; Joseph Choi; G William Wong; Michael J Wolfgang
Journal:  J Bioenerg Biomembr       Date:  2015-12-21       Impact factor: 2.945

3.  Appropriate amino acid mixtures for tryptophan depletion and tyrosine/phenylalanine depletion and the safety of long-term amino acid depletion in humans: reply.

Authors:  Abdulla A-B Badawy
Journal:  Psychopharmacology (Berl)       Date:  2013-11-16       Impact factor: 4.530

4.  Drosophila Vision Depends on Carcinine Uptake by an Organic Cation Transporter.

Authors:  Ratna Chaturvedi; Zhuo Luan; Peiyi Guo; Hong-Sheng Li
Journal:  Cell Rep       Date:  2016-02-25       Impact factor: 9.423

5.  Histamine Receptors Regulate the Activity, Surface Expression, and Phosphorylation of Serotonin Transporters.

Authors:  Balasubramaniam Annamalai; Durairaj Ragu Varman; Rebecca E Horton; Lynette C Daws; Lankupalle D Jayanthi; Sammanda Ramamoorthy
Journal:  ACS Chem Neurosci       Date:  2020-01-22       Impact factor: 4.418

6.  Structural study reveals that Ser-354 determines substrate specificity on human histidine decarboxylase.

Authors:  Hirofumi Komori; Yoko Nitta; Hiroshi Ueno; Yoshiki Higuchi
Journal:  J Biol Chem       Date:  2012-07-05       Impact factor: 5.157

7.  Histamine H3 Inverse Agonist BF 2649 or Antagonist with Partial H4 Agonist Activity Clobenpropit Reduces Amyloid Beta Peptide-Induced Brain Pathology in Alzheimer's Disease.

Authors:  Ranjana Patnaik; Aruna Sharma; Stephen D Skaper; Dafin F Muresanu; José Vicente Lafuente; Rudy J Castellani; Ala Nozari; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

Review 8.  Pharmacological potential of biogenic amine-polyamine interactions beyond neurotransmission.

Authors:  F Sánchez-Jiménez; M V Ruiz-Pérez; J L Urdiales; M A Medina
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

9.  A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with schizophrenia.

Authors:  George M Haig; Earle Bain; Weining Robieson; Ahmed A Othman; Jeffrey Baker; Robert A Lenz
Journal:  Schizophr Bull       Date:  2014-02-10       Impact factor: 9.306

Review 10.  Histamine pharmacology: from Sir Henry Dale to the 21st century.

Authors:  Ekaterini Tiligada; Madeleine Ennis
Journal:  Br J Pharmacol       Date:  2018-12-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.